EUVIMEDEUVIMED entdecken
KohortenstudieStudienprotokoll

Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center

Kelre Wannlen Campos Silva Araújo, Fernanda Carneiro Ronchi, Carlos Eduardo Stecca, Carlos Roberto Naufel Júnior, Paulo Henrique Nocete, Rayssa Helena de Sena, Renata Medeiros Ferreira, Emily Karoline Araujo Nonato

Journal of Gastrointestinal Cancer · 27.04.2026 · 57 (1)

DOI: 10.1007/s12029-026-01474-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 27.04.2026. Verfasst von Kelre Wannlen Campos Silva Araújo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Surgical Digestive, Hospital Universitario Evangelico Mackenzie, Curitiba, PR, Brazil. kelrewannlen@gmail.com. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard treatment for resectable gastric cancer. However, adherence to postoperative cycles is frequently poor, and in the Brazilian public health system, FLOT is reimbursed only in the neoadjuvant setting. This has led to the adoption of an alternative approach delivering all eight cycles preoperatively. We evaluated the feasibility, safety, and outcomes of this exclusive neoadjuvant strategy. METHODS: We retrospectively analyzed 32 patients with resectable gastric cancer treated between 2019 and 2024. Patients were grouped according to the number of neoadjuvant cycles received (≤ 4 vs. > 4). Clinical outcomes included treatment adherence, R0 resection rate, overall survival (OS), disease-free survival (DFS), pathological complete response (ypT0N0) rate, and toxicity. Kaplan-Meier curves, log-rank test, and hazard ratio were used in the analysis. RESULTS: Twenty-one patients (65.6%) completed all eight preoperative cycles. Five patients (15.7%) received ≤ 4 cycles, while 27 (84.3%) received > 4 cycles. The R0 rate was 75%. Median OS was 45.3 months for patients receiving > 4 cycles versus 18.6 months for those with ≤ 4 cycles (p = 0.0096). Median DFS was 41.1 months vs. 18.6 months, respectively (p = 0.028). Pathological complete response was achieved in 9.4% of patients. Toxicity was manageable, although 50% required dose adjustments. CONCLUSION: Delivering all eight cycles of FLOT exclusively in the neoadjuvant setting was feasible and safe in this Brazilian cohort, with high adherence and favorable survival outcomes. This approach may represent a viable alternative in contexts with low adherence to adjuvant treatment or limited access to postoperative chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesBrazilFemaleMaleMiddle AgedFluorouracilAgedOxaliplatinPathologic Complete ResponseDocetaxelLeucovorinAdultFeasibility Studies

Stichwörter der Autor:innen

FLOTGastric cancerNeoadjuvant chemotherapyOncological surgerySurvival rates

Substanzen

FluorouracilOxaliplatinDocetaxelLeucovorin

Autor:innen und Institutionen

  • Department of Medicine, Division of Surgical Digestive, Hospital Universitario Evangelico Mackenzie, Curitiba, PR, Brazil. kelrewannlen@gmail.com.
  • Department of Medicine, Division of Medical Oncology, Hospital Universitario Evangelico Mackenzie, Curitiba, 80730150, Brazil.
  • Department of Medicine, Division of Surgical Digestive, Hospital Universitario Evangelico Mackenzie, Curitiba, PR, Brazil.
  • Department of Medicine, Division of Surgical Oncology, Hospital Universitario Evangelico Mackenzie, Curitiba, PR, Brazil.
  • School of Medicine, Faculdade Evangélica Mackenzie do Paraná, Curitiba, PR, Brazil.

Zitieren

APA

Araújo, K. W. C. S., Ronchi, F. C., Stecca, C. E., Júnior, C. R. N., Nocete, P. H., de Sena, R. H., Ferreira, R. M., & Nonato, E. K. A. (2026). Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center. Journal of Gastrointestinal Cancer, 57(1). https://doi.org/10.1007/s12029-026-01474-2

Vancouver

Araújo KWCS, Ronchi FC, Stecca CE, Júnior CRN, Nocete PH, de Sena RH, et al. Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center. Journal of Gastrointestinal Cancer. 2026;57(1). doi:10.1007/s12029-026-01474-2

BibTeX
@article{Arajo2026,
  author = {Araújo, Kelre Wannlen Campos Silva and Ronchi, Fernanda Carneiro and Stecca, Carlos Eduardo and Júnior, Carlos Roberto Naufel and Nocete, Paulo Henrique and de Sena, Rayssa Helena and Ferreira, Renata Medeiros and Nonato, Emily Karoline Araujo},
  title = {Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2026},
  volume = {57},
  number = {1},
  doi = {10.1007/s12029-026-01474-2}
}
Kostenlos starten →